IQVIA (NYSE:IQV) Reaches New 52-Week High – Here’s What Happened

Shares of IQVIA Holdings Inc. (NYSE:IQV) reached a new 52-week high on Thursday. The stock traded as high as $278.00 and last traded at $278.3740, with a volume of 21,368 shares traded. The stock had previously closed at $276.63.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IQV shares. Weiss Ratings raised shares of IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. UBS Group assumed coverage on shares of IQVIA in a research note on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target for the company. Stifel Nicolaus increased their price target on shares of IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. William Blair raised shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Mizuho raised their price objective on shares of IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a research report on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $276.00.

IQVIA Price Performance

The business has a fifty day moving average price of $262.40 and a 200-day moving average price of $215.24. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $45.95 billion, a PE ratio of 34.60, a PEG ratio of 2.35 and a beta of 1.17.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The company’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 15,581 shares of company stock valued at $3,796,021 over the last 90 days. Company insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently made changes to their positions in IQV. BlackRock Inc. purchased a new position in IQVIA in the 2nd quarter worth $2,811,292,000. Canada Pension Plan Investment Board bought a new stake in IQVIA in the second quarter worth $240,911,000. Bank of America Corp DE bought a new stake in IQVIA in the second quarter worth $235,551,000. Legal & General Group Plc purchased a new stake in IQVIA during the second quarter valued at about $211,342,000. Finally, Bank of New York Mellon Corp purchased a new stake in IQVIA during the second quarter valued at about $180,296,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.